Abstract Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system (CNS) which leads to progressive neurological disability. Our previous studies have demonstrated mitochondrial involvement in MS cortical pathology and others have documented decreased levels of the neuronal mitochondrial metabolite N-acetyl aspartate (NAA) in the MS brain. While NAA is synthesized in neurons, it is broken down in oligodendrocytes into aspartate and acetate. The resulting acetate is incorporated into myelin lipids, linking neuronal mitochondrial function to oligodendrocyte-mediated elaboration of myelin lipids in the CNS. In the present study we show that treating human SH-SY5Y neuroblastoma cells with the electron transport chain inhibitor antimycin A decreased levels of NAA as measured by HPLC. To better understand the significance of the relationship between mitochondrial function and levels of NAA and its breakdown product acetate on MS pathology we then quantitated the levels of NAA and acetate in MS and control postmortem tissue blocks. Regardless of lesion status, we observed that levels of NAA were decreased 25 and 32 % in gray matter from parietal and motor cortex in MS, respectively, compared to controls. Acetate levels in adjacent white matter mirrored these decreases as evidenced by the 36 and 45 % reduction in acetate obtained from parietal and motor cortices. These data suggest a novel mechanism whereby mitochondrial dysfunction and reduced NAA levels in neurons may result in compromised myelination by oligodendrocytes due to decreased availability of acetate necessary for the synthesis of myelin lipids.
Introduction
MS is an inflammatory, demyelinating disease of the CNS that destroys myelin, oligodendrocytes, axons, and neurons [1] . In MS, autoimmune mediated demyelination results in conduction abnormalities and neurological disability. In relapsing remitting forms of disease, conduction is restored after inflammatory episodes due to redistribution of sodium channels and remyelination by oligodendrocytes [2] . Over time, many patients progress to secondary progressive forms of disease. Even though inflammation is decreased in this later stage of disease, chronic damage to axons and neurons results in permanent disability [3] . One of the most critical events leading to damage to axons and neurons and increasing disability over time is the inability to remyelinate exposed axonal segments. Understanding the crosstalk between neurons and oligodendrocytes is critical in order to uncover mechanisms involved in remyelination in the CNS. The neuronal mitochondrial metabolite NAA is a likely candidate for mediating crosstalk between neurons and oligodendrocytes due to the fact that it is synthesized by the enzyme aspartate N-acetyltransferase in neuronal mitochondria and is metabolized by aspartoacylase (ASPA) which is found primarily in oligodendrocytes to give rise to acetate and consequently acetyl-CoA [4] as shown in Fig. 1 . The significance of this relationship has been suggested to involve the use of NAA as an essential substrate for lipid synthesis and myelination in the CNS [5] . This suggestion is supported by the demonstration that NAA contributes acetyl groups for the synthesis of lipids which are in turn incorporated into myelin [6, 7] .
NAA has been found to be decreased in the MS brain as measured in postmortem tissue by HPLC or in vivo by magnetic resonance spectroscopy (MRS) [8] [9] [10] [11] [12] . These studies have also shown that decreased NAA is correlated with disability and cognitive impairment in MS. NAA has traditionally been considered a marker of neuronal integrity and decreases in NAA in neurodegenerative diseases such as MS have been interpreted as measures of axonal loss and brain atrophy. Measurements of both NAA and brain volume by magnetic resonance imaging (MRI) however, have shown that there are considerable decreases in NAA which precede neuronal atrophy [13] . Indeed other MRS studies have shown that decreases in NAA in MS are reversible in remitting phases of disease indicating that decreased NAA is due to a temporary insult such as a dysfunction in neuronal metabolism rather than a more long term insult such as neurodegeneration [14] [15] [16] . Thus, decreased NAA is not merely a marker of neuronal loss but also an indication of dysfunction of neuronal metabolism prior to neuronal degeneration. MS has been traditionally considered a white matter disease but some studies have shown that cortical pathology, including gray matter lesions and cortical atrophy, is extensive [17] [18] [19] . Pathological correlates of cortical damage in MS include fatigue and cognitive impairment [20] . The mechanisms involved in cortical Energy metabolism pathways relevant to this study including glycolysis, the citric acid cycle, the electron transport chain, and the aspartate-malate shuttle are shown schematically. NAA N-acetyl aspartate, ASPA aspartoacylase, Asp-NAT aspartate-N-acetyltransferase, asp L-aspartate, oxa oxaloacetate, CI-CIV complexes I-IV of the electron transport chain (Color figure online) pathology aren't clear, but several studies analyzing postmortem MS tissue have reported mitochondrial damage in MS cortex [21] [22] [23] [24] [25] . In these studies expression of the mitochondrial transcription factor PPARGC1 was decreased in neurons and expression of electron transport chain gene mRNA and protein were significantly decreased in normal appearing gray matter (NAGM) in MS cortex compared to controls. Further, these studies identified deletions of mitochondrial DNA and decreased activity of electron transport chain complexes in NAGM in MS. In the present study we have investigated the potential downstream effects of dysfunctional mitochondria on MS cortical pathology. We have examined the relationship between mitochondrial activity and NAA synthesis and have measured the levels of NAA and its breakdown product, acetate, in postmortem MS and control parietal and motor cortex.
Materials and Methods

Postmortem Tissue
Postmortem frozen brain tissue was obtained from the Rocky Mountain MS Center (Englewood, CO). Donor demographics are shown in Table 1 . Tissue was matched for brain region, age, and postmortem interval as closely as possible. MS and control postmortem cortex was analyzed for the metabolites NAA and acetate. Frozen blocks of brain tissue were sectioned into 60 lm slices on a cryostat. Gray and white matter were separated with a razorblade at the time of sectioning, and stored in separate 50 mL Falcon tubes at -80°C. 50-100 mg tissue was collected for analysis. During tissue collection, selected sections from each sample were affixed to microscope slides rather than being placed into a Falcon tube. Immunohistochemistry with an anti-myelin proteolipid protein (PLP) antibody was performed on these sections to determine lesion status. Frozen sections were fixed in 70 % ethanol and treated with 1 % hydrogen peroxide to quench endogenous peroxidase activity. They were subsequently blocked in 3 % donkey serum and incubated with a monoclonal antibody to PLP (Millipore, Temecula, CA) diluted 1:200 in PBS containing 3 % donkey serum and 0.5 % Triton-X overnight at 4°C. They were then incubated with biotinylated donkey anti-mouse secondary diluted 1:500 overnight at 4°C followed by incubation in Vector Elite ABC horseradish peroxidase solution (Vector Laboratories, Burlingame, CA). PLP was visualized as a brown precipitate developed with the diaminobenzidine (DAB) reaction. [26] . Cell viability was monitored by trypan blue assay. Briefly, 4 9 10 6 SH-SY5Y cells were seeded into 12 well plates until 90 % confluent. The cells were treated with 2.5 lM antimycin A for 1 or 4 h. The cells were detached, centrifuged at 2,000g for 4 min and resuspended in 500 ml fresh medium. The cell suspension was mixed 1:1 with trypan blue solution and incubated for 5 min. Cell numbers were counted under microscope using a hemocytometer. To quantify neurites, SH-SY5Y cells were differentiated with retinoic acid and then treated with 2.5 lM antimycin A for 4 h, fixed, and stained with an antibody to neurofilament (Chemicon, Temecula, CA) and Topro to stain nuclei. Images were acquired with an Olympus FV500 confocal microscope and neurites were counted for 24 cells on each cover slip.
NAA Quantitation by HPLC
The neuronal mitochondrial metabolite NAA was quantitated in postmortem brain tissue and in cultured human SHSY5Yneuroblastoma cells by HPLC. For brain tissue, NAA was quantitated from gray matter from the same tissue blocks analyzed for acetate concentration from both control and MS patients. For SH-SY5Y cells NAA levels were quantified before and after treatment with the mitochondrial electron transport chain inhibitor antimycin A. For HPLC, 50-100 mg postmortem brain tissue or 4 9 10 6 SH-SY5Y cells were homogenized in ice-cold 90 % methanol using pellet pestle, and centrifuged twice at 14,000 rpm for 10 min at 4°C. The supernatant was dried by speed-vac. The powder was then dissolved in 0.5 ml deionized H 2 O and the solution was added to an AG50W 9 8 poly-pre columns (Bio-Rad, Hercules, CA). The column was washed with 1 ml of deionized H 2 O, and all the eluate was collected, lyophilized, and stored at 4°C. For HPLC analysis, each sample was resuspended in 300 ll deionized H 2 O. A Whatman partisil 10 SAX anionexchange column (4.6 mm 9 250 mm) was used in an Agilent 1100 Series HPLC Value System (Agilent Technologies, Santa Clara, CA). The mobile phase consisting of 0.1 M KH 2 PO 4 and 0.025 M KCl at pH 4.5 was prepared before use. After washing the column with 50 % acetonitrile and 50 % deionized H 2 O, the column was conditioned with at least 20-30 column volumes of new mobile phase.
Retention data were collected at a flow-rate of 1.5 ml/min. The flow was monitored with an Agilent 1100 series UV detector at 214 nm. Retention time was 5.10 min and was determined with an NAA standard (Sigma-Aldrich, St. Louis, MO). Peak areas were acquired with Agilent Chemstation software. NAA concentrations for MS and control brain tissue were determined in triplicate and statistical significance was determined with a Student's T test.
Respirometry
A Seahorse Bioscience XF 24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA) was used to conduct real-time measurements of oxygen consumption and extracellular acidification (a measure of glycolysis) in SH-SY5Y cells according to the manufacturer's protocol. The oxygen consumption rate (OCR) in pmol O 2 /min for respiration or the rate of extracellular acidification (ECAR) in mpH/min was measured simultaneously in SH-SY5Y cells before and after the addition of antimycin A. The optimal seeding density of SH-SY5Y cells, based on a measurable O 2 consumption and extracellular acidification rates was established, and both ECAR and OCR show a proportional response with cell number (data not shown). A seeding density of 150,000 cells per well was used for the experiment. OCR and ECAR measurements were made by a solid-state fluorescent oxygen and pH biosensor coupled to a fiber-optic waveguide. On the day of flux analysis, SH-SY5Y cells were checked under light microscope for an even confluent layer. The cells were rinsed twice, resuspended in 625 ll XF assay buffer with 2 mM sodium pyruvate and 4.5 g/L glucose (pH 7.4), and equilibrated for 50 min at 37°C in a non-CO 2 incubator. After cartridge calibration, the plate seeded with SH-SY5Y cells was loaded. After seven baseline measurements of OCR and ECAR, the mitochondrial complex III inhibitor antimycin A (1 lM) was injected into each well. OCR and ECAR values were calculated from four replicates by Seahorse wave software.
Assays for Measuring L-Aspartate and Acetyl-CoA Concentrations Both L-aspartate and acetyl-CoA concentrations were measured by enzyme coupled colorimetric or fluorometric assays based on conversion of NAD ? to NADH. For the aspartate assay, SH-SY5Y cells were seeded in 6 well plates overnight and treated with 2.5 lM antimycin A for 1 h and 4 h. L-Aspartate concentrations were measured using an aspartate assay kit (Sigma, Saint Louis MO). Briefly, cells were washed with ice-cold PBS twice and homogenized in 100 ll of aspartate assay buffer. The samples were centrifuged at 13,000g for 10 min to remove cell debris, and the supernatant was collected. Samples were tested to ensure the readings were within the linear range of the standard curve. Absorbance at 570 nm was measured using a DTX 800 multimode detector (Beckman, Pasadena, CA). For the acetyl-CoA assay SH-SY5Y cells were seeded in 100 mm culture dishes overnight, and treated with 2.5 lM antimycin A for 1 and 4 h. AcetylCoA levels were measured using the picoprobe acetyl CoA assay kit (Biovision, Milpitas CA). Briefly, cells were washed twice with ice-cold PBS and incubated in 500 ll ice-cold cell lysis buffer with 200 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 % Triton X-100, and Halt proteinase inhibitor cocktail (Fisher, Rockford IL) for 5 min. Cells were scraped off the plates and centrifuged at 13,000 g for 10 min. Background generated by free CoASH and succinate-CoA were corrected with 10 ll CoASH quencher in each well for 5 min at room temperature. Fluorescence intensity (kex = 535/ kem = 589 nm) was measured using a DTX 800 multimode detector (Beckman, Pasadena, CA).
Aspartate and acetyl-CoA concentrations were normalized with protein concentration in each sample measured using the Bradford protein assay. The experiments were repeated twice with four replicates in each experiment. A Student's T test was performed to determine statistical significance between aspartate and acetyl-CoA concentrations measured in control and antimycin A treated SH-SY5Y cells.
Assay for Measuring Acetate Concentration
Acetate concentration was quantitated from normal appearing white matter (NAWM) tissue adjacent to the gray matter analyzed for NAA levels. For determination of acetate, 50-100 mg white matter tissue was polytronhomogenized in ddH 2 O, then mixed with absolute ethanol 1:1 (vol:vol) and centrifuged at 10,000 g for 15 min. The supernatants were lyophilized and the dried residues were taken up in ddH 2 O. The concentration of acetate was assayed via the method of Bartelt and Kattermann [27] using a Cary 300 spectrophotometer. Briefly, this assay detects the reduction of NAD ? to NADH, by monitoring sample absorption at 365 nm from the following reactions.
Reactions
Note that Reaction (1), which produces the spectrophotometrically-detected product, is reactant-favored, and is pulled to the right through the combined activities of the other two enzymes (if acetate is present).
Chemicals for these experiments were purchased from Sigma-Aldrich (St. Louis, MO). Buffer containing L-malate, ATP, CoASH and NAD ? was combined with samples from MS and control brains, and a baseline 365 nm absorbance measurement was taken. A malate dehydrogenase / citrate synthase mixture was then added to the cuvettes, and a second 365 nm reading was collected three minutes later. Finally, acetyl-CoA synthetase was added to each cuvette, and incubated for 15 min, at which time a final 365 nm absorbance measurement was recorded. Acetate concentration was determined in duplicate for parietal cortex samples due to availability of tissue, and in triplicate for motor cortex samples and statistical significance was determined with a Student's T test. A Pearson's correlation test (Microsoft Excel) was performed to determine the significance of the correlation between decreased acetate and decreased NAA in MS and control samples.
Results and Discussion
In the present study we provide a link between mitochondrial activity and generation of NAA by mitochondria in SH-SY5Y neuroblastoma cells. NAA was quantitated in SH-SY5Y cells before and after treatment with the electron transport chain inhibitor antimycin A as shown in Fig. 2 . Representative HPLC chromatograms for the NAA standard and for NAA measurements in SH-SY5Y cells are shown in Fig. 2a, b. A standard curve was also run with the NAA standard to be sure that measurements were taken in the linear range as shown in Fig. 2c . Quantitation for NAA measured with our HPLC method in control and antimycin
treated SH-SY5Y cells is shown in Fig. 2d . Our data show that treatment with antimycin A reduced NAA levels in SH-SY5Y cells by 40 % after 1 h and 50 % after 4 h of treatment. Cell viability after antimycin A treatment was determined by trypan blue staining and show that there was no decrease in viable cell numbers between control and treated cells (Fig. 2e) . Control and antimycin A treated SH-SY5Y cells were immunostained for neurofilament to assess the effects of antimycin A on neurite number and length. Images shown in Fig. 2f show that cell morphology and neurites remained intact in treated cells. We also performed respirometry on SH-SY5Y cells and showed that inhibition of complex III cytochrome c reductase with antimycin A decreased the OCR almost threefold from 180 to 60 pmol/min (Fig. 3a) . Non-mitochondrial oxygen consumption was measured after rotenone treatment and found to be 31 pmol/min (data not shown) indicating that antimycin A was partially blocking electron transport. This decreased OCR was sustained for the duration of the experiment (45 min) and as expected, the rate of glycolysis increased twofold in the same cells as shown in Fig. 3b . An increase in the rate of glycolysis provides a mechanism to continue the synthesis of ATP and to compensate for the inhibition of electron transport and ATP production by mitochondria. Our cell culture data presented in Figs. 2 and 3 taken together shows that decreased NAA after treatment with antimycin A was not due to cell death or degeneration of neurites in the SH-SY5Y cells and suggests that decreased mitochondrial activity contributes to the decreased levels of NAA observed. The schematic in Fig. 1 shows metabolic pathways relevant to NAA synthesis and catabolism and their relationship to energy metabolism pathways. Metabolites and pathways measured or inhibited in our study either in SH-SY5Y cells (NAA, acetyl-CoA, aspartate, Complex III, O2 consumption, glycolysis) or in postmortem brain tissue (NAA and acetate) are shown in bold in Fig. 1 . To better understand the effect of electron transport chain inhibition on NAA synthesis, we also quantitated levels of L-aspartate and acetyl-CoA, the substrates for NAA synthesis, in SH-SY5Y cells after treatment with antimycin A for 1 and 4 h as shown in Fig. 3c, d . Antimycin A treatment decreased aspartate levels by over 26 % at both time points and increased acetyl-CoA by 1.5-fold at 1 h and threefold after 4 h. These results suggest that aspartate rather than acetylCoA is limiting for NAA synthesis under these conditions and suggests that aspartate levels may be an important point of regulation for NAA synthesis. Our data in Fig. 3 show that inhibition of complex III leads to decreased OCRs and increased rates of glycolysis in SH-SY5Y cells. Under these conditions we also found that acetyl-CoA accumulated, presumably as a result of increased production of acetyl-CoA by glycolysis and decreased acetyl-CoA utilization by the citric acid cycle due to decreased electron transport chain activity. Decreased aspartate concentrations after antimycin A treatment in SH-SY5Y cells may reflect an imbalance in the NADH/NAD ? ratio which has been shown to occur in cultured cells as a result of increased glycolysis and decreased flow of electrons through the respiratory chain [28] . When the NADH/NAD? ratio is high, aspartate would be less available for NAA synthesis because it would be converted to oxaloacetate and subsequently to malate by the aspartate-malate shuttle to regenerate cytoplasmic NAD ? so that the generation of ATP by glycolysis could continue (Fig. 1) . In fact previous studies have shown that in isolated rat brain mitochondria, the synthesis of NAA is decreased by electron transport chain inhibitors and is related to the production of ATP [29, 30] . These studies support our data which show that NAA levels provide a marker for neuronal metabolism and suggest that decreased NAA previously reported in the MS brain may reflect a metabolic defect in addition to neuronal and axonal loss. This metabolic contribution to reduced NAA in MS has been inferred by an in vivo imaging study which concluded that reduced NAA measured by MRS cannot be entirely attributed to axonal loss alone [31] .
To test the significance of decreased NAA on the potential for remyelination in the MS brain, we next measured NAA levels in gray matter and acetate levels in adjacent white matter from eleven MS and seven control postmortem cortical tissue blocks. Table 1 shows the age, sex, PMI, disease duration, cause of death, and lesion status for the donor tissue analyzed in this study. To determine lesion status, we immunostained sections with an antibody to PLP that were adjacent to the tissue analyzed for NAA and acetate content. Representative PLP immunostaining of NAGM and gray matter subpial lesions are shown in Fig. 4a, b . We then quantitated NAA levels in parietal and motor cortex tissue blocks by HPLC. NAGM was analyzed from parietal cortex in six MS and three control tissue blocks. We also analyzed both NAGM and tissue containing gray matter lesions from motor cortex from five MS and four control tissue blocks. Representative chromatograms for NAA quantitation in gray matter from control and MS cortex are shown in Fig. 5a . Quantitation of HPLC results shows that NAA is decreased by an average of 25 and 32 % in MS parietal and motor cortex respectively compared to controls as shown in Fig. 5b . Our sample size isn't large enough to determine statistical significance of correlations between lesion status and NAA levels, however in our data set NAA levels do not appear to be correlated with lesion status in MS tissue. NAA was decreased in MS cortical gray matter compared to controls in both NAGM and in tissue containing gray matter lesions. Levels of NAA were decreased on average 32 % in NAGM compared to age and sex matched controls. In MS2, MS3, and MS5 which contained subpial gray matter lesions, NAA was decreased by 15, 26, and 25 %, respectively compared to controls (Fig. 6d) . These results suggests that there is mitochondrial impairment leading to decreased NAA even in NAGM which is consistent with previous studies from our group and others which have reported mitochondrial defects in NAGM in MS [21] [22] [23] [24] [25] .
To determine whether decreased NAA could be linked to decreased acetate concentrations in MS, we also measured levels of acetate in NAWM in the same tissue blocks in which we analyzed the NAA levels. We found that acetate concentrations were decreased in MS by 36 % in parietal cortex and 45 % in motor cortex compared to (Fig. 6a) . We then performed a Pearson's correlation analysis which showed that decreased acetate concentrations were correlated with decreased NAA concentrations in the postmortem brain samples (r = 0.64, p \ 0.01) as shown in Fig. 6b . Comparing the data in matched pairs or groups we found that acetate was significantly decreased in nine out of the eleven MS samples compared to matched controls as shown in Fig. 6c . The concentration of acetate in white matter from postmortem MS brain tissue ranged from 0.035 to 0.123 mg/g and was higher on average in controls ranging from 0.098 to 0.139 mg/g as shown in Fig. 6c . These levels of acetate are consistent with brain acetate concentrations reported in another study which found 0.09 mg/g acetate in mouse brain [32] . Interestingly, in this same study, acetate concentrations were decreased to 0.02 mg/g in ASPA knockout mice which are unable to metabolize NAA to aspartate and acetate indicating that acetate concentrations in the brain are related to NAA catabolism. The two MS samples in which we did not detect decreased acetate concentrations were MS6 and MS10. We did not find decreased NAA or acetate in tissue from MS10. The tissue from MS6 was the only sample where we found decreased NAA that was not correlated with decreased acetate concentration. The autopsy report for MS6 noted no evidence of plaques even though the donor was diagnosed with MS indicating this may have been atypical MS.
Our data suggest that neuronal mitochondrial dysfunction may play a role in compromised myelination by oligodendrocytes in MS by limiting the availability of NAA derived acetate required for synthesis of myelin lipids. Acetate is the building block for fatty acid chain synthesis in lipid molecules and the role of acetate in myelination has been demonstrated in several studies. These studies have shown that NAA derived acetate is incorporated into myelin lipids [6, 7] and the lack of acetate due to a defective ASPA enzyme in Canavan's disease leads to dysmyelination [33] . Further, defective myelin lipid synthesis in ASPA knockout mice, a model of Canavan's disease, results from a deficiency of NAA-derived acetate [32] . We have shown that acetate is decreased in NAWM in MS, suggesting that there are alterations in white matter myelin which precede demyelination. Consistent with this finding several studies have reported that fatty acid composition and especially the very long-chain fatty acids, are altered in MS, even in NAWM compared with control brain white matter [34] [35] [36] [37] .
It has been previously shown that signals between neurons and glia are important for myelination. Neuronal activity in the form of action potentials leads to release of ATP by axons activating purinergic receptors on astrocytes. This results in the release of the cytokine leukemia inhibitory factor (LIF) by astrocytes. LIF then signals through LIF receptors on oligodendrocytes to increase expression of myelin proteins and the synthesis of myelin [38] . This intercellular signaling cascade between neurons and glia provides a mechanism for ensuring proper myelination of viable active neurons. The present study adds to the metabolic link between neurons and glia and suggests that NAA from axons may provide both energy necessary for myelination through increased acetate derived acetylCoA and may also promote myelination by increasing acetate for lipid synthesis. Our data suggest that in addition to regulation by neuronal electrical activity, myelination These results, along with our previous findings, suggest that neuronal mitochondrial dysfunction in MS cortex may be central to MS pathology and may contribute to impaired myelination and axonal damage through a loss of NAA. The initiating insult leading to mitochondrial defects in MS is not clear. Whether the initiating insult leading to mitochondrial damage is inflammatory in nature, or pathogen or toxin mediated is still under debate. Cortical lesions were found to be associated with meningeal inflammation in early stage disease in a study which analyzed biopsy material [39] , but other studies analyzing postmortem tissue have not found evidence of inflammation or an association with meningeal inflammation in gray matter cortical lesions [17, 40] . In any case, accumulation of damage to mitochondria has been implicated as a pathological mechanism in MS [41] . Our results suggest that one mechanism by which mitochondrial dysfunction can lead to pathology in MS is through decreased synthesis of NAA. The resulting decrease in NAA in cortical neurons could then decrease acetate and acetyl-CoA availability for energy metabolism and lipid synthesis in adjacent white matter oligodendrocytes. The consequence of these events could impair maintenance and stability of the myelin sheath and lead to demyelination in deeper white matter structures. Our study underscores the need for further research to understand the underlying mechanisms leading to mitochondrial damage in MS and the relationship between neuronal mitochondrial dysfunction and progression of MS pathology.
